Efficacy and safety of GHX02 in the treatment of acute bronchitis: protocol of a phase II, double-blind, randomised placebo-controlled trial

Yee Ran Lyu, Won-Kyung Yang, So Jung Park, Seung-Hyeong Kim, Wee-Chang Kang, In Chul Jung, Yang Chun Park, Yee Ran Lyu, Won-Kyung Yang, So Jung Park, Seung-Hyeong Kim, Wee-Chang Kang, In Chul Jung, Yang Chun Park

Abstract

Introduction: Acute bronchitis is a self-limiting infection of the large airways; cough is the primary symptom, usually lasting for about 3 weeks. Annually, approximately 5% of adults develop acute bronchitis, and its economic burden is substantial. There are also problems of antibiotic abuse in public health systems and symptomatic therapies are commonly prescribed, for which there is insufficient supporting evidence. GHX02 contains four herbs originating from gwaruhaengryeon-hwan, which has been used in the treatment of patients with acute bronchitis in Korea. The objective is to compare the GHX02 and placebo in terms of efficacy and safety, and to determine the appropriate dosage.

Methods and analysis: We planned a phase II, multicentre, dose-finding, double-blind, randomised placebo-controlled trial of two different doses of GHX02 compared with placebo. A total of 150 patients, aged 19-75 years, with a Bronchitis Severity Score (BSS) ≥5 due to acute bronchitis starting within 2 weeks of study enrolment will be recruited from three university-affiliated hospitals across Korea. Participants will be stratified into three patterns using the Korean Standard Tool of Pattern Identifications of Cough and Sputum and randomly assigned to either a high-dose GHX02 group (1920 mg/day), standard-dose GHX02 group (960 mg/day) or placebo group according to a 1:1:1 allocation ratio. Patients will take medications three times daily for 7 days, with two visiting days. The primary outcome measure is a change in BSS from day 0 to day 7. The secondary outcomes are the Questionnaire of Clinical Symptoms of Cough and Sputum, Leicester Cough Questionnaire, frequency of coughing fits, Integrative Medicine Outcome Scale, Integrative Medicine Patient Satisfaction Scale and withdrawal rate of patients with exacerbation. Safety will be assessed by adverse events, vital signs and laboratory examinations.

Ethics and dissemination: The study has been approved by our Institutional Review Board (No. DJDSKH-17-DR-14). The trial results will be disseminated via peer-reviewed journals and the Clinical Research Information Service.

Trial registration number: NCT03310385; Pre-results.

Keywords: Ghx02; acute bronchitis; herbal medicine; randomized controlled trial.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Flow chart of the study procedure.

References

    1. Wenzel RP, Fowler AA. Acute bronchitis. N Engl J Med Overseas Ed 2006;355:2125–30. 10.1056/NEJMcp061493
    1. Park MJ, Rhee CK, Kim YH, et al. . Efficacy and safety of HL301 in the treatment of acute bronchitis and acute exacerbation of chronic bronchitis: a phase 2, randomized, double-blind, placebo-controlled, multicenter study. Curr Med Res Opin 2017;33:919–25. 10.1080/03007995.2017.1295030
    1. Kamin W, Ilyenko LI, Malek FA, et al. . Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. Pediatr Int 2012;54:219–26. 10.1111/j.1442-200X.2012.03598.x
    1. Tackett KL, Atkins A. Evidence-based acute bronchitis therapy. J Pharm Pract 2012;25:586–90. 10.1177/0897190012460826
    1. Kinkade S, Long NA. Acute bronchitis. Am Fam Physician 2016;94:560–5.
    1. Albert RH. Diagnosis and treatment of acute bronchitis. Am Fam Physician 2010;82:1345–50.
    1. Steinman MA, Sauaia A, Maselli JH, et al. . Office evaluation and treatment of elderly patients with acute bronchitis. J Am Geriatr Soc 2004;52:875–9. 10.1111/j.1532-5415.2004.52252.x
    1. Smith SM, Smucny J, Fahey T. Antibiotics for acute bronchitis. JAMA 2014;312:2678–9. 10.1001/jama.2014.12839
    1. Braman SS. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. CHEST Journal 2006;129(Suppl):95S–103.
    1. Smith SM, Schroeder K, Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev 2012;8:CD001831 10.1002/14651858.CD001831.pub4
    1. Cayley WE. Beta2 agonists for acute cough or a clinical diagnosis of acute bronchitis. Am Fam Physician 2017;95:551.
    1. Jiang L, Li K, Wu T. Chinese medicinal herbs for acute bronchitis. Cochrane Database Syst Rev 2012:CD004560 10.1002/14651858.CD004560.pub4
    1. Timmer A, Günther J, Motschall E, et al. . Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev 2013:CD006323 10.1002/14651858.CD006323.pub3
    1. Holzinger F, Chenot JF. Systematic review of clinical trials assessing the effectiveness of ivy leaf (hedera helix) for acute upper respiratory tract infections. Evid Based Complement Alternat Med 2011;2011:1–9. 10.1155/2011/382789
    1. Castro M. Placebo versus best-available-therapy control group in clinical trials for pharmacologic therapies: which is better? Proc Am Thorac Soc 2007;4:570–3. 10.1513/pats.200706-073JK
    1. Moher D, Chan AW. Standard protocol items: recommendations for interventional trials. Wiley Online Library 2014:56–67.
    1. Cheng C-wah, Wu T-xiang, Shang H-cai, et al. . CONSORT extension for chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med 2017;167:112.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010;8:18 10.1186/1741-7015-8-18
    1. Chow S, Wang SJ. Sample Size Calculations Clinical research. New York: Taylor & Francis, 2003.
    1. Matthys H, Kamin W. Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies. Curr Med Res Opin 2013;29:1383–90. 10.1185/03007995.2013.832183
    1. Ministry of Food and Drug Safety, Herbal medicine Evaluation Department. The traditional Korean medicine clinical practice guidelines for antitussives and expectorants. Seoul: Ministry of Food and Drug Safety, 2007:5–15.
    1. Lehrl S, Matthys H, Kamin W, et al. . The BSS—a valid clinical instrument to measure the severity of acute bronchitis. J Lung Pulm Respir Res 2014;1:00016 10.15406/jlprr.2014.01.00016
    1. Leconte S, Ferrant D, Dory V, et al. . Validated methods of cough assessment: a systematic review of the literature. Respiration 2011;81:161–74. 10.1159/000321231
    1. H-j B, B-j L, S-k J, et al. . Retrospective study of patients with cough treated with eunhwayeongyo-tang. Korean J Intern Med 2016;37:961–77.
    1. Yousaf N, Lee KK, Jayaraman B, et al. . The assessment of quality of life in acute cough with the Leicester Cough Questionnaire (LCQ-acute). Cough 2011;7:4 10.1186/1745-9974-7-4
    1. Han JM, Jung IC, Kang W, et al. . Reliability and validity of leicester cough questionnaire Korean version. Chron Respir Dis 2014;11:147–52. 10.1177/1479972314536206
    1. Fischer J, Dethlefsen U. Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial. Cough 2013;9:25 10.1186/1745-9974-9-25
    1. Lyu Y, Park Sjung, Lee EJ, Jeon JH, et al. . A systemic review of clinical trials using medication for acute bronchitis: a pre-study on the development of traditional korean medicine clinical practice guideline. Korean J Med 2017;38:93–111. 10.13048/jkm.17009

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj